Newsroom

Strive to Deliver Breakthroughs

  1. September 27, 2021

    Harbour BioMed Announces Dosing of First Patient of Batoclimab Phase III Trial in Patients with Generalized Myasthenia Gravis

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— September 27, 2021   Harbour BioMed (“HBM”, HKEX: 02142) announced that, the clinical tr...

    View more
  2. September 14, 2021

    Harbour BioMed Announces NMPA Approval of Two IND Applications for Next-Generation Anti-CTLA-4 Antibody HBM4003

    Cambridge, MA, Rotterdam, NL, Suzhou, CN - September 14, 2021   Harbour BioMed (“HBM”, HKEX: 02142) announced that the China Nation...

    View more
  3. September 13, 2021

    Harbour BioMed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003

    Cambridge, MA, Rotterdam, NL, Suzhou, CN - September 13, 2021   Harbour BioMed (“HBM”, HKEX: 02142) announced positive results from...

    View more
  4. September 01, 2021

    Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China

    Cambridge, MA, Rotterdam, NL, Suzhou, CN - September 1, 2021   Harbour BioMed (“HBM”, HKEX: 02142) today announced that the Center ...

    View more
  5. August 31, 2021

    Harbour BioMed Reports 2021 Interim Results: Product Development Breakthroughs Continue to Unlock Value of Integrated Antibody Discovery Platform

    CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands - August 31, 2021   Harbour BioMed (“HBM”, or the "Company”; HKEX: 02...

    View more
  6. July 26, 2021

    HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021

    Cambridge, MA, Rotterdam, NL, Shanghai/Suzhou, CN – July 26, 2021   Harbour BioMed (“HBM”, HKEX: 02142) today announced that t...

    View more
  7. July 21, 2021

    Mount Sinai Entered into Exclusive License Agreement for Neutralizing SARS-CoV-2 Antibody Derived from Harbour BioMed Technology

    Cambridge, MA, Rotterdam, NL, Shanghai/Suzhou, CN – July 21, 2021   Harbour BioMed (“HBM”, HKEX: 02142) today announced that the I...

    View more
  8. July 20, 2021

    Harbour BioMed Appoints Yingying Chen, PhD, as Chief Financial Officer

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 20, 2021   Harbour BioMed (“HBM”, HKEX:02142) announced the appointment of Dr. Yin...

    View more
  9. July 16, 2021

    Harbour BioMed Announces Last Patient Dosing of Phase1b/2a Study of Anti-FcRn Batoclimab for Treating Neuromyelitis Optica Spectrum Disorder

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— July 16, 2021      Harbour BioMed (“HBM”, HKEX: 02142) today announced ...

    View more
  10. July 06, 2021

    Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— July 6, 2021    Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, subst...

    View more